9850FF42-592C-4406-A5B3-52109E0E4E70
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 117.31274638633377
- age_years
- 59
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.613
- MYC_TARGETS_V1+0.530
- G2M_CHECKPOINT+0.480
- E2F_TARGETS+0.468
- WNT_BETA_CATENIN_SIGNALING+0.441
- DNA_REPAIR+0.381
- TGF_BETA_SIGNALING+0.368
- UNFOLDED_PROTEIN_RESPONSE+0.367
- IL6_JAK_STAT3_SIGNALING+0.331
- HEDGEHOG_SIGNALING+0.317
Top 10 suppressed
- KRAS_SIGNALING_DN-0.361
- BILE_ACID_METABOLISM-0.197
- MYOGENESIS-0.146
- SPERMATOGENESIS-0.141
- APICAL_SURFACE-0.131
- FATTY_ACID_METABOLISM-0.099
- PEROXISOME-0.084
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.057
- ESTROGEN_RESPONSE_LATE-0.030
- ESTROGEN_RESPONSE_EARLY-0.014
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 4BB9587B-88CB-4BD9-BE1D-2CDF61337579 | — | — | 0.909 |
| 2 | 6AF1465C-7A6C-4AAF-AFF2-3065EA5B7D0B | — | — | 0.908 |
| 3 | SRR934981 | — | — | 0.898 |
| 4 | B27956E8-3374-4720-9F80-7CE6FE7C7690 | — | — | 0.896 |
| 5 | 7AA08B08-B1DD-47AB-A0F2-850F6DE95093 | — | — | 0.885 |
| 6 | 01169BCB-82ED-4492-9FD0-630CCEA70023 | — | — | 0.881 |
| 7 | 9CD6C527-4E98-427F-9770-7155A1C6CB70 | — | — | 0.875 |
| 8 | 63E967C4-863F-4253-ADFE-3CDC13B6187A | — | — | 0.875 |
| 9 | SRR934869 | — | — | 0.873 |
| 10 | SRR934827 | — | — | 0.872 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 39 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.613 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.530 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.480 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.468 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.441 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.381 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.368 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.367 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.331 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.317 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.317 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.280 | Inavolisib | — uncovered |
| APOPTOSIS | 0.273 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.268 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.263 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.261 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.251 | Idelalisib | — uncovered |
| COMPLEMENT | 0.206 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.203 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.191 | Inavolisib | — uncovered |